A novel triple agonist (GLP-1, GIP, and glucagon receptors). Designed for obesity and type 2 diabetes treatment. Demonstrates significant weight loss and metabolic improvements in clinical trials.
How This Works
Retatrutide is a triple-agonist peptide that activates GLP-1, GIP, and glucagon receptors. This combination increases insulin secretion, reduces appetite, and boosts energy expenditure. Its long half-life (~6 days) supports weekly dosing. By targeting multiple metabolic pathways simultaneously, it enhances fat loss and glucose control more effectively than single- or dual-agonist therapies.
Clinical Benefits & Side Effects
Observations from Phase 2 human clinical trials.
Benefits
- Significant weight loss (up to ~22–24% over 48 weeks).
- Strong improvements in blood sugar control.
- Reductions in blood pressure, cholesterol, and liver fat.
- High response rates across participants.
Side Effects
- Mostly gastrointestinal (nausea, vomiting, diarrhea), especially during dose increases.
- Effects are typically temporary and dose-dependent.
- No major safety concerns reported in trials when properly titrated.
Complementary strategies for optimal metabolic outcomes.
- Maintain a high-protein, nutrient-dense diet.
- Combine resistance and aerobic training.
- Prioritize sleep and stress management.
- Stay hydrated and monitor for GI-related dehydration.
- Track metabolic markers with professional guidance.
Reviews
There are no reviews yet.